Clinical Trials Logo

Brain Tumor, Primary clinical trials

View clinical trials related to Brain Tumor, Primary.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06185686 Not yet recruiting - Clinical trials for Brain Tumor, Primary

Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients

Start date: June 30, 2024
Phase:
Study type: Observational

With modern therapy, the survival rate for pediatric brain tumor patients has significantly improved, with over 70% of patients surviving their disease. However, this progress often comes at the cost of substantial morbidity, with cognitive deficits being the primary obstacle to independent living. Robust predictors of cognitive decline and a comprehensive understanding of the underlying mechanisms of cognitive injury remain elusive. This study will prospectively investigate alterations in brain resting state networks following radiation therapy using functional imaging. The hypothesis is that radiation therapy leads to dose-dependent alterations in functional connectivity in the networks associated with higher level cognition, ultimately leading to cognitive decline.

NCT ID: NCT06106997 Not yet recruiting - Clinical trials for Brain Tumor, Primary

Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow

Start date: January 2024
Phase: N/A
Study type: Interventional

The goal of this observational study is to show the feasibility of an MRI-only workflow in brain radiotherapy. The main question it aims to answer is: - Is an MRI-only workflow based on deep learning sCTs feasible in clinical routine? Participants will be treated as in clinical routine, but treatment planning will be based on sCTs, that are generated from MRI images. The dosimetrical equivalence to the standard CT based workflow will be tested at several points in the study.

NCT ID: NCT01445691 Not yet recruiting - Glioblastoma Clinical Trials

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

Start date: November 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time. When the investigators remove the tumor from your brain, it is important that they remove all of the tumor and not remove parts of normal brain. Sometimes this can be difficult because the tumor can look like normal brain. In some brain tumors, 5-ALA can make the tumors glow red under blue light. This may make it easier for your doctor to take out all of the tumor from your brain. The purpose of this study is to: - Make sure that 5-ALA helps the doctor remove more of the tumor. - Make sure 5-ALA does not cause any side effects. If you do not want to participate in this study, your doctor(s) will still do their best to remove all of the tumor in your brain. Whether or not you join this study will not change your treatment for your brain tumor.